Oregon Health And Science University

November 2020 was a grim time for COVID-19 in the United States, marking the beginning of a brand-new wave of infections fueled by holiday get-togethers that triggered an explosion of cases.

The U.S. Preventive Services Task Force reaffirmed its 2014 recommendation for carotid artery stenosis screening in asymptomatic adults, saying the risks outweigh the benefits. It is listed as a D recommendation.

With two COVID-19 vaccines from Moderna and Pfizer-BioNTech now in circulation and individuals nationwide receiving their initial doses, patients and providers have questions — a lot of questions.

Night-shift workers and other adults who sleep primarily during the day are at increased risk for diabetes, obesity and cardiovascular disease, but the underlying mechanisms are not well understood.

Discontinuation of tyrosine kinase inhibitors after 3 years of use appeared safe for adults with chronic myeloid leukemia who achieved a sustained deep molecular response, according to results of the LAST study published in JAMA Oncology.

Among patients with rheumatoid arthritis, herpes zoster is more common in those treated with upadacitinib than with adalimumab plus methotrexate or with methotrexate alone, according to a speaker at ACR Convergence 2020.

Adults with active thyroid eye disease assigned the human monoclonal antibody teprotumumab experienced improvements in disease outcomes that persisted nearly 1 year after receiving the last trial dose, new study data show.

Avital Y. O’Glasser, MD, FACP, FHM, specializes in perioperative medicine and social media. In this episode, we discuss how her field has adapted amid the pandemic and the role of social media in health care.

As COVID-19 safety precautions and understanding of the virus continue to improve, many cancer centers across the U.S. have been reopening their doors to more patients.

When talking about treating children with unequivocal growth hormone deficiency, who in the absence of GH therapy have little chance of achieving normal adult stature, the overwhelming majority of endocrinologists would say yes, even though GH has some documented risks and may have some potential theoretical risks. With a condition like idiopathic short statue, the benefit of GH therapy, in general, is not as obvious as with GH deficiency. That forces one to possibly reassess the risk vs. benefits.